

Dactinomycin

Essential medicine status

General description

Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).

INN

Dactinomycin

ATC codes

[L01DA01](#)

Medicine type

Chemical agent

EML status history

First added in 1984 ([TRS 722](#)) for [Malignant trophoblastic neoplasms of placenta](#)

Added in 1984 ([TRS 722](#)) for [Rhabdomyosarcoma primary site](#)

Added in 1984 ([TRS 722](#)) for [Malignant neoplasms of kidney, except renal pelvis](#)

Added in 1984 ([TRS 722](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2021 ([TRS 1035](#)) for [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Wikipedia

[Dactinomycin](#)

DrugBank

[Dactinomycin](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

[Malignant trophoblastic neoplasms of placenta](#) [Rhabdomyosarcoma primary site](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)